SAN DIEGO–(BUSINESS WIRE)–Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today participation in the following upcoming investor conferences:
-
Morgan Stanley 21st Annual Global Healthcare Conference, September 11-13, 2023, NY, NY:
- Pipeline management will participate in 1x1s with investors during the conference.
-
UBS Biotechnology Private Company Virtual Symposium, September 20-21, 2023:
- Carmine Stengone, Pipeline’s CEO, will participate in a fireside chat on Thursday, September 21, 2023, at 10:30am ET.
- Pipeline management will also participate in 1x1s with investors during the conference.
About Pipeline Therapeutics
Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. In April 2023, Pipeline announced that it entered into a global license and development agreement with Janssen Pharmaceutica NV (Janssen) for its lead program, PIPE-307, a highly selective M1 antagonist, in central nervous system disorders. The Company’s lead wholly-owned program, PIPE-791, an LPA1 receptor antagonist, is advancing through Phase 1 testing to support treatment of neurological diseases.
For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.
Contacts
Company Contact:
Peter Slover
CFO
ir@pipeline-tx.com
Investor Contact:
Amy Conrad
amy@juniper-point.com